Downloads
Abstract
Background: In fact, the majority of Hepatocellular carcinoma (HCC) cases will progress or be intolerant to first-line systemic therapy. In addition, the standard second-line treatment of HCC or the sequence of systemic therapy after failure of second - line treatment have not been agreed upon. This study explore the progression - free survival (PFS), objective response rate (ORR), overall survival (OS), adverse effects of treatment.
Methods: A retrospective cross-sectional descriptive study on 12 patients with advanced HCC progressed after first - line systemic treatment at Hochiminh City Oncology hospital.
Results: The ORR for second - line treatment was 8.3%, and the disease control rate was 33.3%. Median progression - free survival with second - line therapy (mPFS2) was 3.0 months, and third - line treatment (mPFS3) was 2.1 months. Median overall survival (mOS) after first-line treatment failure was 7.1 months. Up to 80% of reported toxicity cases occurred with patients continued systemic therapy. However, the toxicity was mainly grade 1 - 2 and usually occurs in the later line of treatment.
Conclusion: The choice of systemic treatment in advanced HCC patients progressing after first - line systemic treatment should be fully evaluated based on previous first-line therapy, patient clinical characteristics, and prediction of possible toxicity to be able to make the right treatment decisions and bring the best result for HCC patients.
References
Globocan W, Cancer Today. 2020, Truy cập ngày 15/01/2023, địa chỉ: https://gco.iarc.fr/today/.
Globocan W, Vietnam Fact sheet. 2020, Truy cập ngày 15/01/2023, địa chỉ: https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine. 2020; 382(20): 1894-1905.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2021; 39(3_suppl): 267-267.
Pathak S, Mohamad B. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma. 2021; Volume 8: 1147-1158.
Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021; 75(4): 960-974.
Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022; 167: 1-12.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088): 2492-2502.
Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, et al. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? World J Hepatol. 2022; 14(6): 1074-1086.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2): 282-296.
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.3 | |
| Keywords | Ung thư biểu mô tế bào gan, UTBMTBG, toàn thân, thất bại, bước một, bước hai Hepatocellular carcinoma, HCC, systemic therapy, failure, first - line, second - line |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital